You are here

Recent Pfizer Press Releases

12/5/16 8:00am EDT
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment) trial demonstrating superiority of BOSULIF® (bosutinib) over imatinib as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). The study met its primary endpoint of major molecular response (MMR) at 12 months.

more...
12/3/16 1:00pm EST
New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Data on First Smoothened Inhibitor to Show Clinical Benefit in This Patient Population to be Presented During Oral Session at 2016 ASH Annual Meeting

Today, Pfizer Inc.

more...
12/1/16 10:00am EST
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global Healthcare Conference on Thursday, December 8, 2016 at 2:10 p.m. Eastern Standard Time.

more...
12/1/16 8:00am EST
IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

Collaboration combines IBM Watson's cognitive computing capabilities with Pfizer's scientific knowledge to help scientists generate meaningful insights

12/1/16 8:00am EST
LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to 16 years of age with partial onset seizures. Results showed that adjunctive treatment with LYRICA 10 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. Treatment with LYRICA 2.5 mg/kg/day resulted in a numerical reduction in seizure frequency, which was not statistically significant.

more...
11/30/16 8:30am EST
Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab)

Results Demonstrate Equivalence in Objective Response Rate in Patients with HER2-positive Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint. PF-05280014 is being developed by Pfizer as a potential biosimilar to Herceptin.

more...
11/29/16 8:00am EST
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review

  • If approved by the FDA, avelumab, an investigational immunotherapy, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma (MCC)   
  • Avelumab has previously received FDA Breakthrough Therapy and Fast Track Designations for metastatic MCC, as well as FDA Orphan Drug Designation for MCC  

EMD Serono Inc., the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada

more...
11/21/16 10:11am EST
Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire

  • Kirsten Lund-Jurgensen to succeed Maddaluna

Pfizer Inc. (NYSE:PFE) today announced that Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply will retire from the company after more than 41 years with Pfizer.

more...
11/15/16 8:00am EST
Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis

Detailed Results from Two Phase 3 Studies Featured in Oral & Poster Presentations at 2016 ACR/ARHP Annual Meeting

Pfizer Inc. (NYSE:PFE) announced today that new results from the Phase 3 Oral Psoriatic Arthritis TriaL (OPAL) studies, Broaden and Beyond, will be presented at the 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). OPAL Broaden and OPAL Beyond evaluated the efficacy and safety of XELJANZ® (tofacitinib citrate) in adult patients with active psoriatic arthritis (PsA) who had an inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or to tumor necrosis factor inhibitors (TNFis), respectively.

more...
11/14/16 6:55pm EST
Pfizer Prices $6,000,000,000 Debt Offering

Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of five tranches of notes:

more...
11/14/16 8:00am EST
Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers

Cooperative Research and Development Agreement (CRADA) assesses OX40 agonist, utomilumab and avelumab immuno-oncology assets alone and in various combinations

Pfizer Inc. (NYSE:PFE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

more...
11/13/16 4:57pm EST
Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen

  • Patients Taking Pfizer’s Celebrex (celecoxib) Experienced Fewer Gastrointestinal Events As Compared to Prescription Doses of Ibuprofen and Naproxen
  • Study Findings Dispel Long Standing Perceptions of Excess Cardiovascular Risk Associated With Long Term Use Of Celebrex
  • Results of PRECISION Study Presented at the Annual Meeting of the American Heart Association in New Orleans Provide Important Information for the Treatment of Arthritis

Results of the landmark P

more...
11/11/16 6:00am EST
Pfizer Announces Major Expansion of Humanitarian Assistance Program

Prevenar 13® Vaccine Will Be Available at Lowest Price for Humanitarian Emergencies

Pfizer to Donate Sales Proceeds to Organizations Supporting the Refugee Crisis

 

Pfizer Inc. (NYSE:PFE) announced today a major expansion of its humanitarian assistance program enabling broader access to its vaccine, Prevenar 13, in humanitarian emergency settings by offering its new multi-dose vial (MDV) at what will be the lowest prevailing global price, currently $3.10 per dose. In addition, given the acute need for aid on the ground, Pfizer will donate all sales proceeds for the first year of this program to humanitarian groups undertaking the difficult work of reaching vulnerable populations in emergency settings.

more...
11/10/16 7:59am EST
Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016

New research includes final data from AEGEAN, new real-world data analyses from the ACROPOLIS program, and sub-analyses from the pivotal ARISTOTLE program

11/10/16 2:00am EST
IBRANCE® (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

IBRANCE is the first and only CDK 4/6 inhibitor, a new class of anti-cancer treatments, to be approved in Europe

Pfizer Inc.

more...
11/7/16 6:45am EST
Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis

Results of Phase 3 Studies for Investigational XELJANZ for Psoriatic Arthritis to be Presented at 2016 ACR/ARHP Annual Meeting

Twenty Presentations at 2016 ACR/ARHP Annual Meeting Reinforce Pfizer’s Leadership in Inflammation and Immunology

Pfizer Inc. (NYSE:PFE) announced today that 20 abstracts for XELJANZ® (tofacitinib citrate) will be presented at the upcoming 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). Notably, results from the two pivotal Phase 3 OPAL (Oral Psoriatic Arthritis TriaL) studies of tofacitinib – the only Janus kinase (JAK) inhibitor under investigation for psoriatic arthritis (PsA) – will be presented for the first time.

more...

Pages